Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach

Yeul Hong Kim, J. A. Ajani, D. M. Ota, P. Lynch, J. A. Roth

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background. Adenocarcinomas of the esophagus and the stomach are highly virulent and remain a major health problem worldwide; 5-year survival rates have not changed in the past 30 years. Recently, preoperative chemotherapy has been used to treat these adenocarcinomas. The authors evaluated the usefulness of serial serum carcinoembryonic antigen (CEA) levels in diagnosing these patients and compared the prognosis of patients with high or normal CEA levels. Methods. Ninety consecutive patients with potentially resectable adenocarcinoma of the esophagus or stomach treated with preoperative chemotherapy were evaluated. Serum CEA levels were determined before registration, after each chemotherapy course, every 3 months for the first year after completion of all therapy, and every 6 months thereafter for 5 years. Results. The CEA positivity rate before chemotherapy was 22.2% (20/90); after chemotherapy, it dropped to 10.9% (9/82). An increasing CEA level predicted relapse and correlated well with liver, lung, or pleural involvement in some patients. Most patients with peritoneal involvement did not show elevated levels of CEA. Clinical responses correlated with declining levels of CEA in the patients who showed a negative conversion in CEA level after chemotherapy. Conclusions. An elevated serum CEA level enabled early detection of relapse in the absence of clinical symptoms in patients with adenocarcinoma of the esophagus or the stomach. The level of CEA was also useful in monitoring the response to chemotherapy in patients who had a high CEA level before treatment. Although the pre- and postchemotherapy CEA- positive group had a higher relapse rate than that of other group, the CEA level did not predict resectability or survival. Future research with labeled monoclonal anti-CEA antibodies may prove useful for certain groups of patients.

Original languageEnglish
Pages (from-to)451-456
Number of pages6
JournalCancer
Volume75
Issue number2
DOIs
Publication statusPublished - 1995 Jan 23
Externally publishedYes

Fingerprint

Carcinoembryonic Antigen
Stomach
Drug Therapy
Adenocarcinoma Of Esophagus
Recurrence
Serum
Adenocarcinoma

Keywords

  • carcinoembryonic antigen
  • preoperative chemotherapy
  • resectable adenocarcinoma of the esophagus and the stomach

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. / Kim, Yeul Hong; Ajani, J. A.; Ota, D. M.; Lynch, P.; Roth, J. A.

In: Cancer, Vol. 75, No. 2, 23.01.1995, p. 451-456.

Research output: Contribution to journalArticle

Kim, Yeul Hong ; Ajani, J. A. ; Ota, D. M. ; Lynch, P. ; Roth, J. A. / Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. In: Cancer. 1995 ; Vol. 75, No. 2. pp. 451-456.
@article{feb3e849dda5447c9d5578ce5e2dab48,
title = "Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach",
abstract = "Background. Adenocarcinomas of the esophagus and the stomach are highly virulent and remain a major health problem worldwide; 5-year survival rates have not changed in the past 30 years. Recently, preoperative chemotherapy has been used to treat these adenocarcinomas. The authors evaluated the usefulness of serial serum carcinoembryonic antigen (CEA) levels in diagnosing these patients and compared the prognosis of patients with high or normal CEA levels. Methods. Ninety consecutive patients with potentially resectable adenocarcinoma of the esophagus or stomach treated with preoperative chemotherapy were evaluated. Serum CEA levels were determined before registration, after each chemotherapy course, every 3 months for the first year after completion of all therapy, and every 6 months thereafter for 5 years. Results. The CEA positivity rate before chemotherapy was 22.2{\%} (20/90); after chemotherapy, it dropped to 10.9{\%} (9/82). An increasing CEA level predicted relapse and correlated well with liver, lung, or pleural involvement in some patients. Most patients with peritoneal involvement did not show elevated levels of CEA. Clinical responses correlated with declining levels of CEA in the patients who showed a negative conversion in CEA level after chemotherapy. Conclusions. An elevated serum CEA level enabled early detection of relapse in the absence of clinical symptoms in patients with adenocarcinoma of the esophagus or the stomach. The level of CEA was also useful in monitoring the response to chemotherapy in patients who had a high CEA level before treatment. Although the pre- and postchemotherapy CEA- positive group had a higher relapse rate than that of other group, the CEA level did not predict resectability or survival. Future research with labeled monoclonal anti-CEA antibodies may prove useful for certain groups of patients.",
keywords = "carcinoembryonic antigen, preoperative chemotherapy, resectable adenocarcinoma of the esophagus and the stomach",
author = "Kim, {Yeul Hong} and Ajani, {J. A.} and Ota, {D. M.} and P. Lynch and Roth, {J. A.}",
year = "1995",
month = "1",
day = "23",
doi = "10.1002/1097-0142(19950115)75:2<451::AID-CNCR2820750207>3.0.CO;2-U",
language = "English",
volume = "75",
pages = "451--456",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach

AU - Kim, Yeul Hong

AU - Ajani, J. A.

AU - Ota, D. M.

AU - Lynch, P.

AU - Roth, J. A.

PY - 1995/1/23

Y1 - 1995/1/23

N2 - Background. Adenocarcinomas of the esophagus and the stomach are highly virulent and remain a major health problem worldwide; 5-year survival rates have not changed in the past 30 years. Recently, preoperative chemotherapy has been used to treat these adenocarcinomas. The authors evaluated the usefulness of serial serum carcinoembryonic antigen (CEA) levels in diagnosing these patients and compared the prognosis of patients with high or normal CEA levels. Methods. Ninety consecutive patients with potentially resectable adenocarcinoma of the esophagus or stomach treated with preoperative chemotherapy were evaluated. Serum CEA levels were determined before registration, after each chemotherapy course, every 3 months for the first year after completion of all therapy, and every 6 months thereafter for 5 years. Results. The CEA positivity rate before chemotherapy was 22.2% (20/90); after chemotherapy, it dropped to 10.9% (9/82). An increasing CEA level predicted relapse and correlated well with liver, lung, or pleural involvement in some patients. Most patients with peritoneal involvement did not show elevated levels of CEA. Clinical responses correlated with declining levels of CEA in the patients who showed a negative conversion in CEA level after chemotherapy. Conclusions. An elevated serum CEA level enabled early detection of relapse in the absence of clinical symptoms in patients with adenocarcinoma of the esophagus or the stomach. The level of CEA was also useful in monitoring the response to chemotherapy in patients who had a high CEA level before treatment. Although the pre- and postchemotherapy CEA- positive group had a higher relapse rate than that of other group, the CEA level did not predict resectability or survival. Future research with labeled monoclonal anti-CEA antibodies may prove useful for certain groups of patients.

AB - Background. Adenocarcinomas of the esophagus and the stomach are highly virulent and remain a major health problem worldwide; 5-year survival rates have not changed in the past 30 years. Recently, preoperative chemotherapy has been used to treat these adenocarcinomas. The authors evaluated the usefulness of serial serum carcinoembryonic antigen (CEA) levels in diagnosing these patients and compared the prognosis of patients with high or normal CEA levels. Methods. Ninety consecutive patients with potentially resectable adenocarcinoma of the esophagus or stomach treated with preoperative chemotherapy were evaluated. Serum CEA levels were determined before registration, after each chemotherapy course, every 3 months for the first year after completion of all therapy, and every 6 months thereafter for 5 years. Results. The CEA positivity rate before chemotherapy was 22.2% (20/90); after chemotherapy, it dropped to 10.9% (9/82). An increasing CEA level predicted relapse and correlated well with liver, lung, or pleural involvement in some patients. Most patients with peritoneal involvement did not show elevated levels of CEA. Clinical responses correlated with declining levels of CEA in the patients who showed a negative conversion in CEA level after chemotherapy. Conclusions. An elevated serum CEA level enabled early detection of relapse in the absence of clinical symptoms in patients with adenocarcinoma of the esophagus or the stomach. The level of CEA was also useful in monitoring the response to chemotherapy in patients who had a high CEA level before treatment. Although the pre- and postchemotherapy CEA- positive group had a higher relapse rate than that of other group, the CEA level did not predict resectability or survival. Future research with labeled monoclonal anti-CEA antibodies may prove useful for certain groups of patients.

KW - carcinoembryonic antigen

KW - preoperative chemotherapy

KW - resectable adenocarcinoma of the esophagus and the stomach

UR - http://www.scopus.com/inward/record.url?scp=0028891551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028891551&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19950115)75:2<451::AID-CNCR2820750207>3.0.CO;2-U

DO - 10.1002/1097-0142(19950115)75:2<451::AID-CNCR2820750207>3.0.CO;2-U

M3 - Article

VL - 75

SP - 451

EP - 456

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -